LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Noninvasive Urinary DNA Methylation Test Accurately Diagnoses Bladder Cancer

By LabMedica International staff writers
Posted on 18 Feb 2025
Image: The noninvasive urinary DNA methylation test has high accuracy for the diagnosis of bladder cancer (Photo courtesy of 123RF)
Image: The noninvasive urinary DNA methylation test has high accuracy for the diagnosis of bladder cancer (Photo courtesy of 123RF)

Cystoscopy, though invasive and relatively costly, remains the gold standard for diagnosing bladder cancer. Urine cytology is commonly used as an adjunct diagnostic tool, but its clinical applicability is limited due to its reduced sensitivity in detecting low-grade tumors and the high incidence of false negatives. Early detection is vital to prevent muscle-invasive bladder cancer, which often necessitates radical cystectomy and significantly raises mortality risk. A noninvasive urinary DNA methylation test has now shown high sensitivity and specificity for detecting high-grade or invasive bladder cancer.

A prospective multicenter study led by researchers from the University of Ulsan College of Medicine (Seoul, Korea) assessed the performance of a urinary DNA methylation test (PENK methylation) and compared its diagnostic accuracy to the nuclear matrix protein 22 (NMP22) test and urine cytology. The study, conducted at 10 different sites, involved participants aged 40 and older with hematuria, who underwent cystoscopy within three months between March 11, 2022, and May 30, 2024. The primary outcomes of the study were the sensitivity and specificity of the urinary DNA methylation test for detecting high-grade or invasive bladder cancer. Secondary objectives included evaluating the test's accuracy for overall bladder cancer (across all stages and grades) and comparing its sensitivity and specificity with those of the NMP22 test and urine cytology.

When compared to the NMP22 test or urine cytology, the urinary DNA methylation test demonstrated significantly better sensitivity for detecting both high-grade or invasive bladder cancer and overall bladder cancer. The results, published in JAMA Oncology, revealed that the urinary DNA methylation test had a sensitivity of 89% for detecting high-grade or invasive bladder cancer, outperforming both the NMP22 test and urine cytology with high specificity. While the test exhibited an excellent negative predictive value, its positive predictive value was found to be less optimal. These findings suggest that the urinary DNA methylation test could be highly sensitive and specific for detecting high-grade or invasive bladder cancer.

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Rapid Molecular Testing Device
FlashDetect Flash10

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more